Chinese regulators slap J&J and rivals with a price-fixing fine; Indian court agrees to hear Teva's patent appeal;

@FiercePharma: ICYMI yesterday: The top 10 best-selling vaccines of 2013. Report | Follow @FiercePharma

@TracyStaton: ICYMI, FiercePharma's top weekend news: FDA-nixed diabetes med from Lilly, Boehringer faces rough path to stardom. More | Follow @TracyStaton

@CarlyHFierce: Study: Moral concerns lead barriers to Gardasil uptake in college freshmen. Story from FierceVaccines | Follow @CarlyHFierce

> Chinese regulators slapped Johnson & Johnson ($JNJ), Bausch & Lomb and rivals with a combined 19.6 million yuan (about $3 million) fine for price fixing in the country's contact lens and eyeglass market. Story

> The Delhi High Court agreed to hear Teva's ($TEVA) appeal against Natco Pharma in the companies' ongoing patent infringement case. More

> Bayer received the European Commission's OK to expand approved uses for its thyroid cancer drug Nexavar. Article

> A low dose of antidepressants could provide an alternative treatment for hot flashes in menopausal woman, according to new study results published in JAMA Internal Medicine. More

> The numbers of drugs prescribed for alcoholism in England jumped 79% in the last decade. Item

> Dutch researchers say combining medications to treat symptoms of asthma may be more effective than using one drug. Story

> Zydus kicked off Phase III trials of its LipaGlyn drug for patients with lipodystrophy . Release

Medical Device News

@FierceMedDev: Qiagen and Lilly continue successful string of diagnostics partnerships. More | Follow @FierceMedDev

@VarunSaxena2: Medicare will next year have 140,000 different codes, including nine for injuries caused by turkeys. Story from The Economist | Follow @VarunSaxena2

@MichaelGFierce: 'Nanodaisies' carry two cancer drugs and protect them in the bloodstream. Article | Follow @MichaelGFierce

@EmilyWFierce: FDA will hear Sanofi's second plea for Lemtrada approval. Item | Follow @EmilyWFierce

> Globus Medical unveils new 'self-locking' spinal implant device. Story

> Samsung says its software and hardware will power the digital health ecosystem. More

Biotech News

@FierceBiotech: AbbVie heralds early success with its brain cancer-fighting armed antibody. Story | Follow @FierceBiotech

@JohnCFierce: I have to admit, every time I hear something about 'dendritic cells,' I cringe a little. #ASCO14 | Follow @JohnCFierce

@DamianFierce: FT's "usually well informed sources" say $SHPG is eyeing $NPSP. More | Follow @DamianFierce

@EmilyMFierce: BMJ accuses EMA of watering down open trial data policy. Story | Follow @EmilyMFierce

> Can AstraZeneca's cancer pipeline come through on a $12B promise? Story

> Metabolic disease, cardio expert joins Pfizer's R&D team. Chutes & Ladders

And Finally... Richard III suffered from scoliosis, not a hunchback, say researchers at the University of Leicester. More

Suggested Articles

Acadia's knew it had a winner in psychosis when it called off a trial for its Nuplazid. Now analysts are seeing a blockbuster in the making.

Sandoz would still consider acquisitions, as long as they fit the Novartis unit's focus on generics and biosimilars, CEO Richard Saynor said.

Novartis is planning 80 major drug submissions in key markets over the next three years, and 25 of those could be blockbuster opportunities.